Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist

Bell, Ian M.; Gallicchio, Steven N.; Wood, Michael R.; Quigley, Amy G.; Stump, Craig A.; Zartman, C. Blair; Fay, John F.; Li, Chi-Chung; Lynch, Joseph J.; Moore, Eric L.; Mosser, Scott D.; Prueksaritanont, Thomayant; Regan, Christopher P.; Roller, Shane; Salvatore, Christopher A.; Kane, Stefanie A.; Vacca, Joseph P.; Selnick, Harold G.

doi:10.1021/ml900016y.s001

ml900016y_si_001.pdf (106.91 kB)

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist

journal contribution

posted on 2010-04-08, 00:00 authored by Ian M. Bell, Steven N. Gallicchio, Michael R. Wood, Amy G. Quigley, Craig A. Stump, C. Blair Zartman, John F. Fay, Chi-Chung Li, Joseph J. Lynch, Eric L. Moore, Scott D. Mosser, Thomayant Prueksaritanont, Christopher P. Regan, Shane Roller, Christopher A. Salvatore, Stefanie A. Kane, Joseph P. Vacca, Harold G. Selnick

Incorporation of polar functionality into a series of highly potent calcitonin gene-related peptide (CGRP) receptor antagonists was explored in an effort to improve pharmacokinetics. This strategy identified piperazinone analogues that possessed improved solubility at acidic pH and increased oral bioavailability in monkeys. Further optimization led to the discovery of the clinical candidate 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl]acetamide (MK-3207) (4), the most potent orally active CGRP receptor antagonist described to date.